Nebulized Albuterol Will Not Get NCD Due To Lack Of Data On Patient Subgroups, But Xopenex Loses On Payment Side
This article was originally published in The Pink Sheet Daily
Executive Summary
Medicare Part B coverage policy for nebulized beta adrenergic agonist therapy for lung disease will continue to be the purview of local Medicare claims contractors.